Next Lesson - Membrane Transport and Intracellular Calcium Regulation
Core
Receptor Classes and Time Course
Receptor location and the molecular mechanism a receptor uses predict how quickly a cellular response appears and how long it lasts. Membrane receptors sample the extracellular space, whereas intracellular receptors bind ligands (the molecules that bind a receptor) that have crossed the plasma membrane. The membrane barrier and its signalling logic are developed in Cell Membrane and Signalling.
A practical timescale map follows from effector mechanism (the way a receptor produces its response). Ligand-gated ion channels (channels that open when a ligand binds) change membrane potential in milliseconds because ions flow as soon as the channel opens. G-protein-coupled receptors (GPCRs) usually act through heterotrimeric G proteins (three-part GTP-binding proteins) and second messengers (small signalling molecules made inside the cell) on a seconds-to-minutes scale; their cascade detail belongs in G-Protein Coupled Receptors. Enzyme-linked receptors, the focus of this lesson, alter existing proteins by phosphorylation or by generating cyclic nucleotides, again typically within seconds to minutes. Intracellular receptors for steroid, thyroid, vitamin D and retinoid ligands act principally as ligand-regulated transcription factors (proteins that switch genes on or off). New mRNA and protein must be made, so the physiological onset is commonly measured in hours rather than seconds.
Modification of existing proteins is usually faster than altered transcription and translation. For an unfamiliar hormone or cytokine (a small signalling protein released by immune and other cells), receptor location and effector chemistry predict tempo before pathway detail is memorised.
Typical response times: ion channels act in milliseconds, enzyme-linked membrane receptors start to act in seconds to minutes, and intracellular transcriptional receptors act over hours.
SimpleMed original educational diagram
Receptor Tyrosine Kinases
Receptor tyrosine kinases (RTKs) are single-pass transmembrane proteins (they cross the membrane once) with an extracellular ligand-binding region and a cytosolic tyrosine kinase domain (a region inside the cell that adds phosphate groups to tyrosine amino acids). Many growth factors, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), use this architecture. Many RTKs are restrained in an inactive state until ligand binding promotes dimerisation (pairing of two receptor chains) or higher-order clustering. For many receptors, phosphorylation of the activation loop (a flexible part of the kinase that must be phosphorylated to switch it on) by a partner kinase helps activate the catalytic domain. Phosphorylation between receptor chains is called trans-autophosphorylation. Trans-autophosphorylation is not the only activation mechanism: the epidermal growth factor receptor (EGFR) kinase domains form an asymmetric dimer in which one partner activates the other allosterically (by contacting it and changing its shape). EGFR can still phosphorylate receptor tyrosines to create docking sites, but it does not need its two chains to phosphorylate each other's activation loops to switch on.
The phosphorylated tyrosines (phosphotyrosines) are not decoration. They create docking sites for proteins that carry SH2 (Src homology 2) or PTB (phosphotyrosine-binding) domains, which are protein modules that recognise phosphotyrosine. Bound partners include adaptors (linker proteins) such as Grb2 (growth factor receptor-bound protein 2), enzymes such as phospholipase C-γ (an enzyme that cuts membrane lipids to make second messengers) and phosphatidylinositol 3-kinase (PI3K), and further scaffolds (proteins that hold other proteins together) that assemble local signalling complexes at the membrane. The RTK therefore converts a brief extracellular binding event into a temporary intracellular docking board. Which pathways fire depends on which partners are recruited in that cell type, not on a single universal cascade shared by every RTK.
Classical growth-factor RTKs usually dimerise after ligand binding, but the insulin receptor is already a covalent tetramer (four chains joined by strong chemical bonds) and is switched on when insulin binding changes its shape, after which its kinase domains phosphorylate the receptor. Protein tyrosine phosphatases (enzymes that remove phosphate groups from tyrosines) undo these docking sites, so without continued kinase input the signal collapses.
Insulin as a Worked Example
The insulin receptor is the textbook example of an enzyme-linked receptor with clear branch logic. It is synthesised as a precursor that is cleaved and assembled into a preformed disulphide-linked (held together by sulphur-sulphur bonds) α2β2 heterotetramer (a complex of four chains of two types) comprising two αβ half-receptors. The α subunits bind insulin outside the cell; the β subunits span the membrane and carry the tyrosine kinase domains. Insulin therefore does not need to bring two separate receptor chains together, because they are already joined. Insulin binding rearranges the preformed complex and activates the β-subunit kinases.
Autophosphorylation of the β chains creates binding sites for insulin receptor substrate (IRS) proteins, which the receptor then phosphorylates. IRS polypeptides are scaffolds (proteins that hold other proteins together) rather than the final effectors (the molecules that carry out the response). Once tyrosine-phosphorylated by the receptor, they present docking sites for SH2-domain proteins, notably the adaptor Grb2 and the p85 regulatory subunit of class IA PI3K (the form of class I PI3K that binds phosphotyrosine docking sites). From that single membrane event the cell can open both a mitogenic (cell-division-promoting) Ras-MAPK branch and a metabolic PI3K-Akt branch. Tissue context decides the dominant readout: adipocytes and myocytes (muscle cells) emphasise glucose uptake and storage, whereas other cells may couple the same receptor family more strongly to growth programmes.
Remember the preformed α2β2 RTK, the IRS scaffold and the split into MAPK versus PI3K outputs, because together they explain how one receptor drives both growth and metabolic effects. Endocrine-axis control and diabetes pharmacology belong elsewhere.
MAPK and PI3K
The Ras-Raf-MEK-ERK cascade is the core mitogen-activated protein kinase (MAPK) branch used by many RTKs. A common entry is Grb2 bound to phosphotyrosine, carrying Sos, a guanine nucleotide exchange factor (a protein that helps a G protein swap GDP for GTP). Sos activates membrane-associated Ras (a small GTP-binding protein) by promoting GDP release so that GTP can bind. Ras-GTP recruits and helps activate Raf family kinases. Raf phosphorylates MEK (MAPK/ERK kinase), and MEK phosphorylates ERK (extracellular signal-regulated kinase). Active ERK phosphorylates cytosolic targets and also enters the nucleus to modify transcription factors. The cascade is a three-tier kinase relay: each step can phosphorylate many downstream molecules, so a modest number of active receptors can produce a large ERK output.
The PI3K-Akt branch has different chemistry and a different first job. Class I PI3K phosphorylates phosphatidylinositol bisphosphate (PIP2) to trisphosphate (PIP3) in the inner leaflet (inner half) of the plasma membrane. PIP3 recruits proteins with a pleckstrin homology (PH) domain, a lipid-binding region, including Akt (protein kinase B) and its upstream activating kinases. Once activated, Akt phosphorylates targets that promote survival, growth and, in insulin-responsive tissues, redistribution of glucose transporters and engagement of anabolic enzymes. Lipid phosphatases such as PTEN (phosphatase and tensin homologue) reverse PIP3 to PIP2 and are therefore strong brakes on this branch.
MAPK is often a growth and gene-expression route; PI3K-Akt often supports survival and metabolism. Cells run both with cross-talk. For insulin, PI3K-Akt dominates acute metabolic adjustment, while Ras-MAPK contributes more to longer-term transcription and growth.
JAK-STAT and Guanylyl Cyclase
Not every cytokine receptor is itself a kinase. Many cytokine receptors have no intrinsic enzymatic domain. Instead they associate non-covalently with Janus kinases (JAKs, kinases that sit on the receptor tail). Ligand-induced receptor clustering brings JAKs close enough to activate one another by phosphorylation. Active JAKs then phosphorylate tyrosines on the receptor tails. STAT (signal transducer and activator of transcription) transcription factors bind these phosphotyrosines and are then phosphorylated by JAKs. The phosphorylated STATs pair up (dimerise) and move to the nucleus to regulate gene expression. The route is therefore membrane-started but transcriptionally finished.
An RTK carries its own kinase domain; a cytokine receptor borrows activity from an associated JAK. Both create phosphotyrosine docking sites, but catalytic ownership differs. JAK-STAT is a direct cytokine-to-nucleus module, although its transcription-dependent physiological output is slower than post-translational RTK effects.
Guanylyl cyclases are enzymes that generate the second messenger cyclic guanosine monophosphate (cGMP) rather than phosphotyrosine docking sites. Membrane receptor guanylyl cyclases, typified by receptors for natriuretic peptides (peptides that promote sodium and water loss), bind extracellular ligand and convert GTP to cGMP through an intracellular catalytic domain. Soluble guanylyl cyclase in the cytosol is activated by nitric oxide (a signalling gas) that has diffused from a neighbouring cell. In both the membrane and soluble forms, cGMP activates protein kinase G (a cGMP-activated kinase) and can modulate ion channels and phosphodiesterases (enzymes that break down cyclic nucleotides). The shared idea is enzyme-linked production of a diffusible cyclic nucleotide, terminated when phosphodiesterases hydrolyse cGMP.
Intrinsic RTK kinase domains compared with JAK-associated cytokine receptors that phosphorylate STAT transcription factors at the membrane.
SimpleMed original educational diagram
Intracellular Receptors
Lipophilic (fat-soluble) hormones and related ligands do not need a receptor enzyme in the membrane to start signalling. Steroid hormones, 1,25-dihydroxyvitamin D and retinoids cross the plasma membrane by diffusion. Thyroid hormone enters cells mainly through transporter proteins such as MCT8 (monocarboxylate transporter 8). All four then bind intracellular receptors of the nuclear receptor superfamily (a family of receptors that act on DNA inside the cell). Some receptors reside mainly in the cytoplasm in complexes with chaperones (helper proteins that hold the receptor in shape) and translocate after ligand binding. Others are already nuclear and are switched from repressive to activating states when ligand arrives. In either case the ligand-receptor complex binds specific DNA sequences termed hormone response elements (HREs) and recruits co-activators or co-repressors (proteins that boost or dampen transcription) that remodel local chromatin and transcription.
The physiological tempo follows the mechanism. Even when ligand is present, new proteins appear only after transcription and translation. Responses such as altered enzyme complement, transporter expression or developmental gene programmes therefore unfold over hours. That slower onset is not a defect; it is appropriate for set-point changes in metabolism, differentiation and long-term endocrine tone. Some steroids also act quickly at the cell membrane without changing gene expression (non-genomic actions), but the main mechanism remains ligand-regulated transcription at HREs.
Steroid, thyroid, vitamin D and retinoid pathways share the intracellular-receptor and HRE pattern despite different upstream physiology. The core sequence is lipophilic ligand, receptor binding, DNA response element, transcriptional change and a delayed change in the proteome (the full set of proteins in the cell).
Amplification and Termination
Signalling would be useless if one occupied receptor produced only one modified protein. Amplification is built into enzyme-linked routes. A single active RTK can phosphorylate many substrate molecules. Each kinase in a MAPK cascade can modify many MEK or ERK molecules. One active guanylyl cyclase can generate many cGMP molecules. Amplification lets sparse extracellular ligands control abundant intracellular targets, but it also makes termination essential. Without off-switches, every brief binding event would become a permanent cellular state.
Termination uses several complementary tools. Protein phosphatases remove the phosphates that created docking sites and activated kinases, restoring the pre-signal covalent state. Lipid phosphatases such as PTEN clear PIP3. Phosphodiesterases destroy cGMP and, in the GPCR pathways covered elsewhere, cyclic AMP (cAMP). GTP-binding proteins such as Ras hydrolyse GTP to GDP, with help from GTPase-activating proteins (proteins that speed up this breakdown), and thereby leave the active conformation. Receptor internalisation by endocytosis removes receptors from the cell surface, after which they may be recycled or degraded. Negative feedback, including ERK-driven expression of inhibitors or STAT-induced SOCS proteins (suppressors of cytokine signalling), further limits prolonged output.
Receptor location tells you whether a ligand acts from outside or enters the cell. Effector mechanism identifies the first productive step. Enzyme-linked receptors start by rewiring existing proteins within seconds to minutes, although pathways that end in transcription, such as JAK-STAT, take longer; intracellular receptors act through gene expression and change the proteome more slowly. This map predicts response speed, amplification and the required off-switches.
Reviewed by: Dr. Marcus Judge
- 166
